Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon ...

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...

Presenting at Technology Networks’<i/> Cell and Gene Therapy 2025 Symposium, Dr. Andrew Mancini, senior corporate development ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

Lipid receptor SR-B1 identified as a potential immunotherapy target to boost NK cell antitumor response in advanced ovarian ...

General and administrative (G&A) expenses were $12.4 million for the first quarter of 2025, which included $5.1 million of restructuring expenses in March 2025. Non-cash stock-based compensation ...

GI Innovation, a South Korean biotech company, announced on May 13 that it has been selected as a semi-finalist in the XPRIZE ...

Cancer is the rapid, uncontrollable proliferation of mutated cells that spread within tissue and eventually throughout the body. Cancer types are dependent | Immunology ...

There is a consistent need from researchers to manufacture a cGMP virus to support the advancement of gene therapies.

A global study suggests that using small molecule inhibitors followed by epigenetic modifiers may significantly improve ...